Major shareholder announcement
Dec 19, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of December 18, 2019 holds a total 991,557 shares in the Company, corresponding to 4.96% of the share capital and that Danske Bank as of December 18, 2019 controls 7.42% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
Dec 18, 2019
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today received Fast Track designation from the US Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM).
Orphazyme s arimoclomol receives us fast track ...
Read moreMajor shareholder announcement
Nov 28, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of November 27, 2019 holds a total 999,606 shares in the Company, corresponding to 5.00% of the share capital and that Danske Bank as of November 27, 2019 controls 7.53% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
Nov 19, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for arimoclomol, an investigational drug for the treatment of Niemann-Pick Disease Type C (NPC).
Orphazyme receives breakthrough therapy designation
Read moreFinancial calendar 2020
Nov 1, 2019
Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the company expects to publish financial reports according to the following schedule.
Read moreMajor shareholder announcement
Oct 2, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of October 1, 2019 holds a total 998,962 shares in the Company, corresponding to 4.99% of the share capital and that Danske Bank as of October 1, 2019 controls 7.74% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event
Sep 17, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, has been invited to participate in a meeting hosted by the National Organization for Rare Disorders (NORD) and the Critical Path Institute (C-PATH) to launch their joint initiative: the Rare Disease Cures Accelerator Data and Analytics Platform (RDCA-DAP). Funded by the US Food and Drug Administration (FDA), the goal of RDCA-DAP is to accelerate the process of moving therapies from bench to bedside for rare diseases.
Orphazyme cmo to speak at fda funded rare disease...
Read moreOrphazyme announces Interim Report First Half 2019
Aug 28, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights.
Orphazyme announces interim report first half 2019
Interim report first half 2019
Read moreOrphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital
Aug 27, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has entered into a structured debt facility (Loan Agreement) with Kreos Capital VI (UK) Limited (Kreos) to secure funding of EUR 9 million. Orphazyme plans to draw down the loan on September 1, 2019. Proceeds from the loan will be used to fund the on-going preparations for filing of arimoclomol in the US and Europe, commercial planning, and for general corporate purposes.
Orphazyme strengthens balance sheet with eur 9 milli
Read moreOrphazyme Interim Report First Half 2019 Presentation
Aug 21, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Interim Report First Half 2019. The presentation will be followed by a Q&A session.
Orphazyme interim report first half 2019 presentation
Read more